Header Logo

Connection

ERICH M STURGIS to Oropharyngeal Neoplasms

Back to Details
This is a "connection" page, showing publications ERICH M STURGIS has written about Oropharyngeal Neoplasms.
ERICH M STURGIS
Connection Strength
13.028
Oropharyngeal Neoplasms
  1. Prevention and Screening of HPV Malignancies. Semin Radiat Oncol. 2021 10; 31(4):297-308.
    View in: PubMed
    Score: 0.437
  2. Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncol. 2021 09; 120:105397.
    View in: PubMed
    Score: 0.429
  3. Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. JAMA Otolaryngol Head Neck Surg. 2020 07 01; 146(7):656-664.
    View in: PubMed
    Score: 0.401
  4. Projected oropharyngeal carcinoma incidence among middle-aged US men. Head Neck. 2019 09; 41(9):3226-3234.
    View in: PubMed
    Score: 0.371
  5. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. Cancer. 2017 Dec 15; 123(24):4886-4894.
    View in: PubMed
    Score: 0.330
  6. Medical Care Cost of Oropharyngeal Cancer among Texas Patients. Cancer Epidemiol Biomarkers Prev. 2017 09; 26(9):1443-1449.
    View in: PubMed
    Score: 0.329
  7. Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 2016 11 15; 122(21):3411-3412.
    View in: PubMed
    Score: 0.304
  8. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. 2016 06 01; 122(11):1702-7.
    View in: PubMed
    Score: 0.298
  9. Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. J Clin Oncol. 2016 06 01; 34(16):1848-54.
    View in: PubMed
    Score: 0.296
  10. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol. 2015 Sep; 51(9):832-8.
    View in: PubMed
    Score: 0.283
  11. Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer. 2015 Oct 01; 121(19):3455-64.
    View in: PubMed
    Score: 0.283
  12. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. Clin Cancer Res. 2015 Jun 15; 21(12):2861-9.
    View in: PubMed
    Score: 0.282
  13. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol. 2015 Jul; 51(7):662-7.
    View in: PubMed
    Score: 0.280
  14. Management of the lymph node-positive neck in the patient with human papillomavirus-associated oropharyngeal cancer. Cancer. 2014 Oct 01; 120(19):3082-8.
    View in: PubMed
    Score: 0.263
  15. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol. 2014 May; 50(5):380-6.
    View in: PubMed
    Score: 0.256
  16. Epidemiology of oral-cavity and oropharyngeal carcinomas: controlling a tobacco epidemic while a human papillomavirus epidemic emerges. Otolaryngol Clin North Am. 2013 Aug; 46(4):507-20.
    View in: PubMed
    Score: 0.246
  17. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer. 2013 Jul 15; 119(14):2593-601.
    View in: PubMed
    Score: 0.243
  18. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013 Jan 29; 8:21.
    View in: PubMed
    Score: 0.240
  19. Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. Head Neck. 2013 Jun; 35(6):794-9.
    View in: PubMed
    Score: 0.230
  20. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 2012 Apr; 22(2):128-42.
    View in: PubMed
    Score: 0.226
  21. The epidemic of HPV-associated oropharyngeal cancer is here: is it time to change our treatment paradigms? J Natl Compr Canc Netw. 2011 Jun 01; 9(6):665-73.
    View in: PubMed
    Score: 0.213
  22. Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. Head Neck. 2011 Jun; 33(6):847-55.
    View in: PubMed
    Score: 0.202
  23. HPV vaccination. Inaccurate assumptions about oropharyngeal cancer. BMJ. 2009 Nov 02; 339:b4525.
    View in: PubMed
    Score: 0.191
  24. Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys. 2005 Jul 01; 62(3):665-71.
    View in: PubMed
    Score: 0.142
  25. Stepped Behavioral and Biological Screening for Oral Oncogenic HPV DNA in Middle-aged and Elderly Adults: A Feasibility Study. Cancer Prev Res (Phila). 2023 03 01; 16(3):127-132.
    View in: PubMed
    Score: 0.120
  26. Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic. Expert Rev Anticancer Ther. 2022 07; 22(7):751-761.
    View in: PubMed
    Score: 0.115
  27. Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. Cancer Med. 2023 01; 12(1):569-583.
    View in: PubMed
    Score: 0.115
  28. Genetic variants in CYP2B6 and HSD17B12 associated with risk of squamous cell carcinoma of the head and neck. Int J Cancer. 2022 08 15; 151(4):553-564.
    View in: PubMed
    Score: 0.114
  29. Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662.
    View in: PubMed
    Score: 0.114
  30. Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. 2022 08; 35(8):1045-1054.
    View in: PubMed
    Score: 0.112
  31. Risk factors associated with patient-reported fatigue among long-term oropharyngeal carcinoma survivors. Head Neck. 2022 04; 44(4):952-963.
    View in: PubMed
    Score: 0.112
  32. Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. Cancer. 2021 12 01; 127(23):4470-4480.
    View in: PubMed
    Score: 0.108
  33. Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. JAMA Otolaryngol Head Neck Surg. 2021 07 01; 147(7):615-623.
    View in: PubMed
    Score: 0.107
  34. Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngol Head Neck Surg. 2021 05 01; 147(5):469-478.
    View in: PubMed
    Score: 0.106
  35. An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas. Sci Rep. 2021 01 19; 11(1):1802.
    View in: PubMed
    Score: 0.104
  36. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021 04 15; 127(8):1228-1237.
    View in: PubMed
    Score: 0.103
  37. Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. Cancer. 2021 03 15; 127(6):850-864.
    View in: PubMed
    Score: 0.103
  38. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. Br J Cancer. 2021 02; 124(3):628-633.
    View in: PubMed
    Score: 0.102
  39. National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. Head Neck. 2021 01; 43(1):108-115.
    View in: PubMed
    Score: 0.102
  40. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncol. 2020 11; 110:104797.
    View in: PubMed
    Score: 0.100
  41. Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States. Head Neck. 2020 09; 42(9):2321-2329.
    View in: PubMed
    Score: 0.099
  42. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol. 2020 07; 148:133-139.
    View in: PubMed
    Score: 0.099
  43. Lymphopenia during radiotherapy in patients with oropharyngeal cancer. Radiother Oncol. 2020 04; 145:95-100.
    View in: PubMed
    Score: 0.097
  44. A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer. Mol Carcinog. 2019 12; 58(12):2276-2285.
    View in: PubMed
    Score: 0.095
  45. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. Radiother Oncol. 2020 01; 142:133-139.
    View in: PubMed
    Score: 0.094
  46. Lymphocyte telomere length predicts clinical outcomes of HPV-positive oropharyngeal cancer patients after definitive radiotherapy. Carcinogenesis. 2019 07 06; 40(6):735-741.
    View in: PubMed
    Score: 0.094
  47. Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas. Oral Oncol. 2019 09; 96:21-26.
    View in: PubMed
    Score: 0.094
  48. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 07 10; 37(20):1753-1774.
    View in: PubMed
    Score: 0.091
  49. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. Cancer. 2019 05 01; 125(9):1536-1546.
    View in: PubMed
    Score: 0.090
  50. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 01 05; 393(10166):40-50.
    View in: PubMed
    Score: 0.089
  51. Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys. 2018 11 15; 102(4):1029-1035.
    View in: PubMed
    Score: 0.087
  52. A TGF-?1 genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer. Int J Cancer. 2018 09 15; 143(6):1327-1334.
    View in: PubMed
    Score: 0.086
  53. Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Semin Radiat Oncol. 2018 04; 28(2):108-113.
    View in: PubMed
    Score: 0.086
  54. TGF?1 Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy. Clin Cancer Res. 2018 05 01; 24(9):2225-2233.
    View in: PubMed
    Score: 0.085
  55. Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature. Hum Pathol. 2018 06; 76:149-155.
    View in: PubMed
    Score: 0.084
  56. Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. Cancer. 2018 03 01; 124(5):960-965.
    View in: PubMed
    Score: 0.084
  57. Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog. 2018 03; 57(3):361-369.
    View in: PubMed
    Score: 0.083
  58. Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients =65?years old. Radiat Oncol. 2017 Sep 09; 12(1):150.
    View in: PubMed
    Score: 0.082
  59. Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2017 10 01; 141(7):1355-1364.
    View in: PubMed
    Score: 0.081
  60. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2017 Jul - Aug; 7(4):246-253.
    View in: PubMed
    Score: 0.080
  61. Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. Oral Oncol. 2017 03; 66:75-80.
    View in: PubMed
    Score: 0.079
  62. Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. Sci Rep. 2017 01 03; 7:39765.
    View in: PubMed
    Score: 0.079
  63. E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. Mol Carcinog. 2017 04; 56(4):1335-1343.
    View in: PubMed
    Score: 0.079
  64. The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma. Int J Cancer. 2017 Feb 01; 140(3):504-512.
    View in: PubMed
    Score: 0.078
  65. A functional variant at the miRNA binding site in E2F1 gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma. Mol Carcinog. 2017 03; 56(3):1100-1106.
    View in: PubMed
    Score: 0.078
  66. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. Radiother Oncol. 2016 07; 120(1):48-55.
    View in: PubMed
    Score: 0.076
  67. A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer. Oncotarget. 2016 Jun 07; 7(23):34472-9.
    View in: PubMed
    Score: 0.076
  68. Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. Oncotarget. 2016 Jun 07; 7(23):35015-25.
    View in: PubMed
    Score: 0.076
  69. Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst. 2016 08; 108(8).
    View in: PubMed
    Score: 0.075
  70. Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinoma. Head Neck. 2016 08; 38(8):1139-44.
    View in: PubMed
    Score: 0.074
  71. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016 04; 17(4):440-451.
    View in: PubMed
    Score: 0.074
  72. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):360-367.
    View in: PubMed
    Score: 0.074
  73. Depression and Oropharynx Cancer Outcome. Psychosom Med. 2016 Jan; 78(1):38-48.
    View in: PubMed
    Score: 0.073
  74. Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. Head Neck. 2016 04; 38 Suppl 1:E1554-61.
    View in: PubMed
    Score: 0.073
  75. Prognostic value of pretherapy platelet elevation in oropharyngeal cancer patients treated with chemoradiation. Int J Cancer. 2016 Mar 01; 138(5):1290-7.
    View in: PubMed
    Score: 0.072
  76. Impact of selective neck dissection on chronic dysphagia after chemo-intensity-modulated radiotherapy for oropharyngeal carcinoma. Head Neck. 2016 06; 38(6):886-93.
    View in: PubMed
    Score: 0.072
  77. Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. Int J Cancer. 2015 Nov 15; 137(10):2454-61.
    View in: PubMed
    Score: 0.071
  78. A functional variant at miRNA-122 binding site in IL-1a 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer. Eur J Cancer. 2015 Jul; 51(11):1415-23.
    View in: PubMed
    Score: 0.070
  79. Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response. Oral Oncol. 2015 Feb; 51(2):195-201.
    View in: PubMed
    Score: 0.068
  80. Influence of smoking history on imaging characteristics among patients with human papillomavirus-positive oropharyngeal cancer: a blinded matched-pair analysis. J Comput Assist Tomogr. 2014 Sep-Oct; 38(5):667-73.
    View in: PubMed
    Score: 0.067
  81. Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. Cancer Epidemiol Biomarkers Prev. 2014 Jan; 23(1):160-71.
    View in: PubMed
    Score: 0.064
  82. Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol. 2014 Feb; 122(2):96-103.
    View in: PubMed
    Score: 0.064
  83. Genetic variants in TNF-a promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy. Int J Cancer. 2014 Apr 15; 134(8):1907-15.
    View in: PubMed
    Score: 0.063
  84. Potentially functional variants of p14ARF are associated with HPV-positive oropharyngeal cancer patients and survival after definitive chemoradiotherapy. Carcinogenesis. 2014 Jan; 35(1):62-8.
    View in: PubMed
    Score: 0.063
  85. Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma. Cancer Res. 2013 Oct 01; 73(19):5996-6003.
    View in: PubMed
    Score: 0.062
  86. The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer. Cancer. 2013 Sep 01; 119(17):3162-9.
    View in: PubMed
    Score: 0.061
  87. Variants in nucleotide excision repair core genes and susceptibility to recurrence of squamous cell carcinoma of the oropharynx. Int J Cancer. 2013 Aug 01; 133(3):695-704.
    View in: PubMed
    Score: 0.060
  88. Interleukin-10 promoter variants predict HPV-positive tumors and survival of squamous cell carcinoma of the oropharynx. FASEB J. 2013 Jun; 27(6):2496-503.
    View in: PubMed
    Score: 0.060
  89. MicroRNA variants increase the risk of HPV-associated squamous cell carcinoma of the oropharynx in never smokers. PLoS One. 2013; 8(2):e56622.
    View in: PubMed
    Score: 0.060
  90. Pre-microRNA variants predict HPV16-positive tumors and survival in patients with squamous cell carcinoma of the oropharynx. Cancer Lett. 2013 Apr 28; 330(2):233-40.
    View in: PubMed
    Score: 0.059
  91. p16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck. Head Neck. 2013 Nov; 35(11):1527-33.
    View in: PubMed
    Score: 0.059
  92. Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):415-20.
    View in: PubMed
    Score: 0.058
  93. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer. 2013 Jan 01; 119(1):81-9.
    View in: PubMed
    Score: 0.057
  94. Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. PLoS One. 2012; 7(4):e35522.
    View in: PubMed
    Score: 0.057
  95. Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx. Cancer. 2012 Mar 15; 118(6):1684-92.
    View in: PubMed
    Score: 0.054
  96. An examination of male and female odds ratios by BMI, cigarette smoking, and alcohol consumption for cancers of the oral cavity, pharynx, and larynx in pooled data from 15 case-control studies. Cancer Causes Control. 2011 Sep; 22(9):1217-31.
    View in: PubMed
    Score: 0.054
  97. Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer. Clin Cancer Res. 2010 Mar 01; 16(5):1416-22.
    View in: PubMed
    Score: 0.049
  98. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer. 2009 Dec 15; 115(24):5723-33.
    View in: PubMed
    Score: 0.048
  99. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer. 2008 Dec 15; 113(12):3307-14.
    View in: PubMed
    Score: 0.045
  100. Functional variants of the NEIL1 and NEIL2 genes and risk and progression of squamous cell carcinoma of the oral cavity and oropharynx. Clin Cancer Res. 2008 Jul 01; 14(13):4345-52.
    View in: PubMed
    Score: 0.044
  101. The role of human papillomavirus in squamous carcinoma of the head and neck. Curr Oncol Rep. 2006 Mar; 8(2):130-9.
    View in: PubMed
    Score: 0.037
  102. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. Br J Cancer. 2020 10; 123(9):1456-1463.
    View in: PubMed
    Score: 0.025
  103. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. 2016 Feb 15; 122(4):534-45.
    View in: PubMed
    Score: 0.018
  104. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013 Jan; 36(1):66-76.
    View in: PubMed
    Score: 0.015
  105. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer. 2012 Aug 01; 131(3):E251-8.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.